BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
2040 results:

  • 1. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
    Squicciarini T; Villani R; Apollonio B; Fucci L; Zambetti M; Rossini M; Pinto R; Tommasi S; De Roma I; Strippoli S; Guida M
    Front Immunol; 2024; 15():1369531. PubMed ID: 38799429
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
    Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
    Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
    Thomas MF; Slowikowski K; Manakongtreecheep K; Sen P; Samanta N; Tantivit J; Nasrallah M; Zubiri L; Smith NP; Tirard A; Ramesh S; Arnold BY; Nieman LT; Chen JH; Eisenhaure T; Pelka K; Song Y; Xu KH; Jorgji V; Pinto CJ; Sharova T; Glasser R; Chan P; Sullivan RJ; Khalili H; Juric D; Boland GM; Dougan M; Hacohen N; Li B; Reynolds KL; Villani AC
    Nat Med; 2024 May; 30(5):1349-1362. PubMed ID: 38724705
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Experimental study for inorganic and organic profiling of toy makeup products: Estimating the potential threat to child health.
    Mercan S; Kilic MD; Zengin S; Yayla M
    Environ Sci Pollut Res Int; 2024 May; 31(23):33975-33992. PubMed ID: 38696006
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-ctla4 Therapies.
    Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
    Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
    Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.
    Gudd CLC; Mitchell E; Atkinson SR; Mawhin MA; Turajlic S; Larkin J; Thursz MR; Goldin RD; Powell N; Antoniades CG; Woollard KJ; Possamai LA; Triantafyllou E
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580334
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
    Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
    Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?
    Reschke R; Deitert B; Enk AH; Hassel JC
    Front Immunol; 2024; 15():1385781. PubMed ID: 38562921
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations.
    Liu D; Cao M; Wang H; Cao W; Zheng C; Li Y; Wang Y
    BMC Med; 2024 Mar; 22(1):137. PubMed ID: 38528540
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
    Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
    Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
    Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Linear IgA bullous dermatosis associated with immunotherapy.
    Momin B; Nguyen TF; Glade D; Messer A
    Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
    Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
    Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Zhang W; Wang S
    Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
    Haugh A; Daud AI
    Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
    Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
    Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Dermatologic manifestations in pediatric patients with inflammatory bowel disease.
    Afarideh M; Bartoletta K; Tollefson MM
    Pediatr Dermatol; 2024; 41(2):234-242. PubMed ID: 38326222
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 102.